Bionano Genomics Statistics
Share Statistics
Bionano Genomics has 101.99M shares outstanding. The number of shares has increased by 143.28% in one year.
| Shares Outstanding | 101.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 24.44% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 101.34M |
| Failed to Deliver (FTD) Shares | 513.85K |
| FTD / Avg. Volume | 18.93% |
Short Selling Information
The latest short interest is 9.83M, so 9.64% of the outstanding shares have been sold short.
| Short Interest | 9.83M |
| Short % of Shares Out | 9.64% |
| Short % of Float | 9.7% |
| Short Ratio (days to cover) | 3.81 |
Valuation Ratios
The PE ratio is -0.28 and the forward PE ratio is -0.54.
| PE Ratio | -0.28 |
| Forward PE | -0.54 |
| PS Ratio | 1.79 |
| Forward PS | 0.6 |
| PB Ratio | 0.67 |
| P/FCF Ratio | -0.51 |
| PEG Ratio | n/a |
Enterprise Valuation
Bionano Genomics Inc. has an Enterprise Value (EV) of 99.43M.
| EV / Earnings | -0.43 |
| EV / Sales | 2.75 |
| EV / EBITDA | -0.47 |
| EV / EBIT | -0.46 |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 1.4, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.4 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.73 |
| Total Debt / Capitalization | 42.06 |
| Cash Flow / Debt | -1.79 |
| Interest Coverage | -42.05 |
Financial Efficiency
Return on equity (ROE) is -2.42% and return on capital (ROIC) is -122.63%.
| Return on Equity (ROE) | -2.42% |
| Return on Assets (ROA) | -1.08% |
| Return on Capital (ROIC) | -122.63% |
| Revenue Per Employee | 104.99K |
| Profits Per Employee | -675.85K |
| Employee Count | 344 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | 62.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84% in the last 52 weeks. The beta is 2.38, so Bionano Genomics 's price volatility has been higher than the market average.
| Beta | 2.38 |
| 52-Week Price Change | -84% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 41.93 |
| Average Volume (20 Days) | 2.71M |
Income Statement
In the last 12 months, Bionano Genomics had revenue of $36.12M and earned -$232.49M in profits. Earnings per share was $-6.81.
| Revenue | 36.12M |
| Gross Profit | 9.57M |
| Operating Income | -215.25M |
| Net Income | -232.49M |
| EBITDA | -213.60M |
| EBIT | -215.25M |
| Earnings Per Share (EPS) | -6.81 |
Balance Sheet
The company has $17.95M in cash and $79.41M in debt, giving a net cash position of -$61.47M.
| Cash & Cash Equivalents | 17.95M |
| Total Debt | 79.41M |
| Net Cash | -61.47M |
| Retained Earnings | -581.21M |
| Total Assets | 87.36M |
| Working Capital | 14.03M |
Cash Flow
In the last 12 months, operating cash flow was -$125.18M and capital expenditures -$1.69M, giving a free cash flow of -$126.87M.
| Operating Cash Flow | -125.18M |
| Capital Expenditures | -1.69M |
| Free Cash Flow | -126.87M |
| FCF Per Share | -3.72 |
Margins
Gross margin is 26.49%, with operating and profit margins of -595.98% and -643.74%.
| Gross Margin | 26.49% |
| Operating Margin | -595.98% |
| Pretax Margin | -643.57% |
| Profit Margin | -643.74% |
| EBITDA Margin | -591.44% |
| EBIT Margin | -595.98% |
| FCF Margin | -351.29% |
Dividends & Yields
BNGO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2837.5% |
| FCF Yield | -513.17% |
Analyst Forecast
The average price target for BNGO is $1, which is 316.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 316.7% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 7, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Aug 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -14.75 |
| Piotroski F-Score | 3 |